A phase 1 study to evaluate the safety, pharmacokinetics, and efficacy of the first-in-class cyclin A/B RxL inhibitor CID-078, an orally bioavailable, cell-permeable macrocycle. This is an ASCO ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results